Literature DB >> 7824040

Effects of MPP+ on catecholamine levels in adrenal glands and heart of rats.

M Kujacic1, A Carlsson.   

Abstract

The effects of MPP+ (2.5-20 mg/kg) on the adrenal glands and heart were investigated in rats. At various periods after s.c. drug administration the rats were decapitated and tissue catecholamine levels were determined by means of HPLC with electrochemical detection. Adrenal dopamine (DA) levels were reduced at 2-8 h after MPP+ administration, but this decrease was followed by an elevation after 16 h and return to the control values after one week. Three successive injections of MPP+ caused a statistically significant elevation in adrenal DA, one day, with a tendency to elevation four and seven days after the last injection, whereas a severe (up to 96%) decrease in heart noradrenaline (NA) was found one day after the last injection. Seven days after the last injection a 50% depletion of NA in the heart was still observed. Pretreatment with GBR 12909 (30 mg/kg, 4h) blocked the MPP+ (10 mg/kg, 2 h) induced reduction of adrenal DA levels, but at the same time GBR 12909 failed to block the effects of MPP+ in the heart. One day after three successive daily injections of MPP+ (10 mg/kg each), the DA-uptake inhibitor GBR 12909 (30 mg/kg, 6 h) could still induce an increase in adrenal DA. MPP+ appears to lack persistent cytotoxic action in the adrenal medulla but rather to cause a transient inhibition of DA synthesis followed by a compensatory stimulation. The inhibition can be blocked by specific inhibitor of the DA-uptake mechanism, suggesting a direct effect of MPP+ taken up by adrenomedullary cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7824040     DOI: 10.1007/bf00175029

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  17 in total

1.  Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells.

Authors:  J F Reinhard; E J Diliberto; O H Viveros; A J Daniels
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

2.  Effect of MPTP on primate chromaffin cells in vitro: relevance for adrenal medullary cell transplantation.

Authors:  M F Notter; M Kaniuki; S Y Felten; J T Hansen; D M Gash
Journal:  Restor Neurol Neurosci       Date:  1991-01-01       Impact factor: 2.406

3.  The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action.

Authors:  P H Andersen
Journal:  Eur J Pharmacol       Date:  1989-08-03       Impact factor: 4.432

4.  Characterization of cellular transport, subcellular distribution, and secretion of the neurotoxicant 1-methyl-4-phenylpyridinium in bovine adrenomedullary cell cultures.

Authors:  J F Reinhard; E J Diliberto; A J Daniels
Journal:  J Neurochem       Date:  1989-04       Impact factor: 5.372

5.  Comparative behavioral, biochemical and pigmentary effects of MPTP, MPP+ and paraquat in Rana pipiens.

Authors:  A Barbeau; L Dallaire; N T Buu; J Poirier; E Rucinska
Journal:  Life Sci       Date:  1985-10-21       Impact factor: 5.037

6.  Peripheral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its main metabolite 1-methyl-4-phenylpyridinium ion (MPP+) in the rat.

Authors:  S Algeri; S Ambrosio; P Garofalo; P Gerli
Journal:  Eur J Pharmacol       Date:  1987-09-11       Impact factor: 4.432

7.  Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on dopamine metabolism in mouse and rat striatum.

Authors:  E Pileblad; B Fornstedt; D Clark; A Carlsson
Journal:  J Pharm Pharmacol       Date:  1985-10       Impact factor: 3.765

8.  Mechanisms of toxicity and cellular resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium in adrenomedullary chromaffin cell cultures.

Authors:  J F Reinhard; S W Carmichael; A J Daniels
Journal:  J Neurochem       Date:  1990-07       Impact factor: 5.372

Review 9.  MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease.

Authors:  M Gerlach; P Riederer; H Przuntek; M B Youdim
Journal:  Eur J Pharmacol       Date:  1991-12-12       Impact factor: 4.432

10.  Acute changes in dopamine levels in rat adrenal glands after administration of dopamine receptor agonists and antagonists.

Authors:  M Kujacic; K Svensson; L Löfberg; A Carlsson
Journal:  Eur J Pharmacol       Date:  1990-02-27       Impact factor: 4.432

View more
  2 in total

1.  Striatal and urinary DOPAC/DA ratio may indicate a long-lasting DA release enhancement by MPP+ and MPTP.

Authors:  S P Bagchi
Journal:  Neurochem Res       Date:  1998-02       Impact factor: 3.996

2.  Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice.

Authors:  R Zwart; S Verhaagh; M Buitelaar; C Popp-Snijders; D P Barlow
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.